GleamWall
中文EN

GPCR Structure Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1888886 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-39.5%
TTM EPS YoY-6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.5%
ROA-27.1%
ROIC (approx.)-32.3%
Asset turnover—

Leverage & solvency

Liabilities / assets8.4%
Debt / equity0.00x
Current ratio11.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$134.55M$100.06M$66.51M$68.69M$58.99M$54.71M$42.87M$33.49M
SG&A expense$21.78M$18.57M$22.87M$17.57M$14.80M$15.74M$13.44M$13.57M
Operating income-$156.33M-$118.63M-$89.38M$23.99M-$73.79M-$70.45M-$56.31M-$47.06M
Pretax income-$144.59M-$105.92M-$75.78M$33.17M-$65.60M-$61.52M-$46.73M-$36.34M
Income tax$171,000$234,000$190,000$170,000$108,000$139,000$98,000$136,000
Net income-$144.76M-$106.16M-$75.97M$33.00M-$65.71M-$61.66M-$46.83M-$36.48M
EBITDA-$156.27M-$118.08M-$88.80M$24.40M-$73.43M-$70.16M-$56.04M-$46.79M
EPS (basic)-0.66-0.49-0.35—-0.37-0.36-0.27—
EPS (diluted)-0.66-0.49-0.35—-0.37-0.36-0.27—
Weighted avg. shares (diluted)218.58M217.96M217.33M—175.47M172.65M172.05M—
Balance sheet
Cash & equivalents$222.03M$272.64M$316.17M$799.62M$102.91M$147.02M$152.12M$169.51M
Short-term investments$1.02B$1.07B$1.14B$646.57M$696.13M$639.47M$684.76M$714.01M
Current assets$1.28B$1.37B$1.49B$1.57B$814.02M$799.30M$849.62M$891.21M
PP&E, net$10.26M$6.33M$6.37M$6.65M$4.67M$3.46M$3.52M$3.48M
Total assets$1.33B$1.43B$1.51B$1.58B$832.16M$816.44M$866.55M$903.33M
Current liabilities$107.10M$66.11M$56.98M$63.28M$57.53M$39.03M$36.49M$36.02M
Total liabilities$112.55M$71.01M$61.03M$67.54M$62.14M$44.36M$41.91M$38.49M
Shareholders' equity$1.22B$1.35B$1.45B$1.52B$770.02M$772.08M$824.64M$864.84M
Shares outstanding214.09M213.66M213.21M212.51M182.03M172.70M172.61M171.86M
Cash flow statement
Operating cash flow-$101.70M-$120.11M$15.23M-$64.42M-$51.00M-$54.56M-$52.23M-$36.47M
Capital expenditure$3.65M-$42,000$1.18M$1.50M$1.57M$232,000$314,000$16,000
Free cash flow-$105.34M-$120.07M$14.05M-$65.91M-$52.57M-$54.79M-$52.54M-$36.48M
Investing cash flow$50.36M$74.50M-$496.95M$56.14M-$49.32M$48.94M$34.03M$33.23M
Financing cash flow$734,000$2.08M-$1.74M$704.99M$56.20M$517,000$809,000$615,000
Depreciation & amortization$61,000$551,000$576,000$412,000$356,000$291,000$274,000$273,000
Stock-based compensation$12.73M$12.63M$11.64M$8.07M$7.50M$7.51M$5.92M$5.83M

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.